<DOC>
	<DOCNO>NCT02576327</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety additional aprepitant standard antiemetic regimen Autologous Hematopoietic Stem Cell Transplantation .</brief_summary>
	<brief_title>A Study Evaluating Efficacy Safety Aprepitant Autologous Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>Chemotherapy-induced nausea vomiting ( CINV ) serious complication treatment hematological malignancy . Although aprepitant show control CINV highly emetogenic therapy solid tumor , antiemetic effect aprepitant hematological chemotherapy still clear . In multi-central perspective randomize control study , investigator try evaluate efficacy safety additional aprepitant standard antiemetic regimen Autologous Hematopoietic Stem Cell Transplantation .</detailed_description>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Tropisetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Men woman &gt; /= 18 year , &lt; 65 year Patients lymphoma receive autologous hematopoietic stem cell transplantation first time ECOG 02 TBIL , AST ALT &lt; 2.5fold upper normal range Female male subject childbearing potential must agree use medically accept method adequate contraception . Signed informed consent Prior autologous/ allogeneic hematopoietic stem cell transplantation lymphoma Women pregnant breast feeding . Serious uncontroled infection Serious complication Severe renal hepatic disease Severe mental nervous system disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Aprepitant</keyword>
	<keyword>Chemotherapy-induced nausea vomiting ( CINV )</keyword>
	<keyword>Autologous Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Hematological Malignancies</keyword>
</DOC>